AFX-0169

AFX-0169 is a topical small molecule formulation of the vasodilator minoxidil, developed by Afecta Pharmaceuticals for the prevention of chemotherapy-induced alopecia (CIA). As an agonist of ATP-sensitive inward rectifier potassium channels (KATP channels), minoxidil induces hyperpolarization of vascular smooth muscle cells, leading to vasodilation and increased local blood flow to the hair follicles. This enhanced microcirculation is believed to stimulate hair follicle epithelial cells and promote the transition from the telogen (resting) phase to the anagen (growth) phase of the hair cycle. While minoxidil is a standard treatment for androgenetic alopecia, AFX-0169 is a proprietary formulation specifically optimized for use in patients undergoing chemotherapy. According to Afecta's pipeline, the product is considered marketed, representing a specialized application of minoxidil in the oncology supportive care setting.

Other names

minoxidil